ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
“Allowance of this patent significantly strengthens our intellectual property portfolio around our innovations for an intragastric balloon system and is a significant accomplishment, ensuring comprehensive protection,” stated
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about our future intellectual property protection measures. These and additional risks and uncertainties are described more fully in the company's filings with the
CONTACTS
ReShape Lifesciences Investor Contact:
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
917-633-6086
mmiller@rxir.com
![](https://ml.globenewswire.com/media/ZTMyMjBiM2QtNjU5OS00ZWMyLWFmM2EtMWRkMzZjZWI3NjA0LTEwMTg2NDU=/tiny/ReShape-Lifesciences-Inc.png)
Source: ReShape Lifesciences Inc